EUVIMEDEUVIMED entdecken
Crossref

Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering

Mitra Chitsazan, Mandana Chitsazan iD, Christopher P Cannon

Cardiovascular Research · 14.08.2026 · 122 (11) · 1409-1411

DOI: 10.1093/cvr/cvag138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 14.08.2026. Verfasst von Mitra Chitsazan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Iran University of Medical Sciences, Tehran, Iran. Die Arbeit nennt 13 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Mandana Chitsazan

Zitieren

APA

Chitsazan, M., Chitsazan, M., & Cannon, C. P. (2026). Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering. Cardiovascular Research, 122(11), 1409-1411. https://doi.org/10.1093/cvr/cvag138

Vancouver

Chitsazan M, Chitsazan M, Cannon CP. Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering. Cardiovascular Research. 2026;122(11):1409-1411. doi:10.1093/cvr/cvag138

BibTeX
@article{Chitsazan2026,
  author = {Chitsazan, Mitra and Chitsazan, Mandana and Cannon, Christopher P},
  title = {Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering},
  journal = {Cardiovascular Research},
  year = {2026},
  volume = {122},
  number = {11},
  pages = {1409--1411},
  doi = {10.1093/cvr/cvag138}
}
Kostenlos starten →